Asthma Research
Asthma is a common chronic inflammatory disease of the respiratory system that affects approximately 22 million people in US. It has been classified as a complex genetic condition that is determined by the interaction of numerous genes along with environmental factors.
Asthma Research Products Targets
- Adenosine A2B Receptor (7)
- Adenosine A2A Receptor (11)
- Matrix Metalloprotease (16)
- Caspase (9)
- Elastase (1)
- Lipoxygenase (8)
- Leukotriene and Related Receptor (13)
- Bradykinin Receptor (12)
- Cytokine Receptor (4)
- Urokinase (2)
- Deubiquitinating Enzyme (12)
- Aminopeptidase (5)
- Angiotensin-Converting Enzyme (8)
- Carboxypeptidase (1)
- Calpain (7)
- Histamine H4 Receptor (12)
- Histamine H3 Receptor (22)
- Histamine H2 Receptor (10)
- Histamine H1 Receptor (17)
- Adenosine A3 Receptor (8)
- Adenosine A1 Receptor (12)
- IαB Kinase (6)
- Calcium-Activated Potassium (KCa) Channel (19)
- Dipeptidyl Peptidase IV (1)
- Cathepsin (9)
- gamma-Secretase (9)
- ADAMs (1)
- Proteasome (5)
Products for Asthma Research - Page 19
- Cat.No. Product Name Information/Activity
-
BCC5139
Balicatib
Balicatib(AAE-581) is a potent and selective inhibitor of cathepsin K; 10-100 fold more potent in cell-based enzyme occupancy assays than against cathepsin B, L, and S.
-
BCC1141
CA 074
CA-074 is a potent inhibitor of cathepsin B with a Ki of 2 to 5 nM.
-
BCC1127
E 64d
Aloxistatin (E64d) is a cell-permeable and irreversible broad-spectrum cysteine protease inhibitor.
-
BCC2361
L 006235
Potent cathepsin K inhibitor
-
BCC2362
SID 26681509
SID 26681509 is a potent, reversible, competitive, and selective inhibitor of human cathepsin L with an IC50 of 56 nM. SID 26681509 inhibits in vitro propagation of malaria parasite Plasmodium falciparum and inhibits Leishmania major with IC50s of 15.4 μM and 12.5 μM, respectively. SID 26681509 shows no inhibitory activity against cathepsin G.
-
BCC6137
HBX 41108
924296-39-9
-
BCC2086
IU1
IU1 is a special Usp14 inhibitor with an IC50 of 4-5 μM.
-
BCC2087
LDN 57444
LDN-57444 is a reversible, competitive and site-directed inhibitor of ubiquitin C-terminal hydrolase L1 (UCH-L1), with an IC50 of 0.88 μM and a Ki of 0.40 μM; LDN-57444 also suppresses UCH-L3 activity, with an IC50 of 25 μM.
-
BCC4924
Mitoxantrone HCl
Mitoxantrone dihydrochloride is a topoisomerase II inhibitor; also inhibits protein kinase C (PKC) activity with an IC50 of 8.5 μM.
-
BCC2088
NSC 632839 hydrochloride
NSC632839 is a nonselective isopeptidase inhibitor, which inhibits USP2, USP7, and SENP2 with EC50s of 45±4 μM, 37±1 μM, and 9.8±1.8 μM, respectively.


